Maalox suspension 4.3ml mini stick 6 pcs black currant

Description

Composition
Active substance:
1 mini packet comprises: algeldrat (aluminum hydroxide) (as hydrated alumina) – 460.0 mg (equivalent to 230.0 mg of alumina), magnesium hydroxide – 400.0 mg ;.
Excipients:
Sucrose 64% – 4913 mg sorbitol liquid (non-crystallizable) – 200 mg, xanthan gum – 2.4 mg, guar – 5.6 mg natural flavoring – 13.2 mg Sodium chloride – 4.8 mg.
Description:
Oral suspension from white to pale yellow, homogeneous.
Product form:
Oral suspension. 4.3 ml (6 g) suspension in a mini-bag (sachet) of aluminum foil coated with polypropylene and polyethylene. At 6, 10, 20, 30 or 40 mini-packages (sachets), together with instructions for use in a cardboard box.
Contraindications
Hypersensitivity to the active substances and other ingredients. Severe renal insufficiency. Hypophosphatemia. Deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption (due to the presence in the formulation of sorbitol and sucrose). Childhood and adolescence (15 years).
Carefully
Aluminum hydroxide may cause constipation, overdose magnesium salts can lead to the weakening of the intestinal peristalsis; in patients at high risk (patients with renal insufficiency, elderly patients), high doses of the drug can cause or exacerbate bowel obstruction and ileus. Aluminum hydroxide is poorly absorbed in the gastrointestinal tract, so in patients with normal renal function, systemic exposure is rare. Prolonged treatment, use of excessive doses of 2 drugs or the use of the normal dose of the drug due to weak admission phosphates with food can lead to phosphate deficiency (due to aluminum binding phosphate), which is accompanied by increased bone resorption and hypercalciuria with the risk of osteomalacia. Treatment of patients at risk of developing a phosphate deficiency or prolonged use of the drug should be carried out under medical supervision. If the kidney function (while taking the drug Maaloks® mini may increase plasma concentrations of magnesium and aluminum, and long-term use of the drug Maaloks® small in high doses, including in high therapeutic doses may encephalopathy, dementia, microcytic anemia or aggravation osteomalacia, caused by dialysis). In patients with porphyria undergoing hemodialysis. During pregnancy (see. Section “Pregnancy and lactation”) In Alzheimer’s disease in diabetes (in connection with the content of the drug in the composition of sucrose) (see. Section “Special Instructions”).
Indications
Heartburn, acid regurgitation content.
Interaction with other drugs
With quinidine: while the use of quinidine may increase serum concentrations of quinidine and development quinidine overdose.
Since blockers of H2-histamine receptors, propranolol, atenolol, cefdinir, cefpodoxime, metoprolol, chloroquine, prostacyclin diflunisalom, digoxin, bisphosphonates, ethambutol, isoniazid, fluoroquinolones, sodium fluoride, glucocorticosteroids (described for prednisolone and dexamethasone), indomethacin, ketoconazole, lincosamides , phenothiazine antipsychotics, penicillamine, rosuvastatin, iron salts, levothyroxine: while receiving with the drug decreases Maaloks® mini suction listed in Chez drugs in the gastrointestinal tract. In the case of a 2-hour interval between administration of these drugs and drug Maaloks® mini and 4-hour interval between the reception and the fluoroquinolone drug Maaloks® small in most cases this can avoid undesirable interaction.
With polystyrenesulfonate (kayeksalatom) when used together with the drug Maaloks® mini polystyrenesulfonate (kayeksalatom) should be careful because of the possible risk of reducing the effectiveness of the binding resin and potassium of metabolic alkalosis in patients with renal failure (for magnesium hydroxide and aluminum hydroxide) and obstruction intestine (aluminum hydroxide).
Citrate: the combination of aluminum hydroxide with citrate may increase the plasma concentrations of aluminum, especially in patients with renal insufficiency.
Overdose
Symptoms of acute overdose combination of aluminum hydroxide and magnesium salts include diarrhea, abdominal pain and vomiting. In patients at risk of high doses of the drug can cause or exacerbate bowel obstruction or ileus (see. Section ”
Carefully “).
Treatment: aluminum and magnesium excreted in the urine. Treatment of acute overdose carried out using a replenishment liquid losses and forced diuresis. Patients with kidney failure need to hemodialysis or peritoneal dialysis.
pharmachologic effect
Pharmacological group:
Antacid.
Pharmacodynamics:
Maaloks® mini is antacids, do not have systemic effects. Its antacid capacity is 20 meq H + mini-package [determining in vitro by the method Rosset-Rice (Rosset-Rice)]. Preparation neutralize free hydrochloric acid, without causing secondary hypersecretion of hydrochloric acid. In connection with an increase in pH when it is receiving reduced peptic activity of gastric juice. Has also absorbent and protective action, thanks to which reduced the impact of damaging factors on the mucosa of the stomach and duodenum. Maaloks® mini capable eliminate or attenuate heartburn for several hours. Thanks to its balanced composition with regard to the influence on the motility of the gastrointestinal tract Maaloks® mini usually does not cause constipation. Magnesium hydroxide and algeldrat passed X-rays.
Pharmacokinetics:
Hydroxides of aluminum and magnesium antacids topical considered practically not absorbed when taken in recommended doses and, accordingly, has no systemic effects.
Pregnancy and breast-feeding
Pregnancy: the animals received a clear indication of the presence of teratogenic effect in aluminum hydroxide and magnesium hydroxide. At the moment, did not reveal any specific teratogenic effects when using the drug Maaloks® mini during pregnancy, however, due to the lack of clinical experience, its use during pregnancy is possible only in low doses and short-term and in cases where the potential benefits of its use to the mother justifies the potential risk to the fetus.
Lactation: using as recommended by the absorption of magnesium hydroxide and aluminum salts in the mother combinations is limited, so the drug Maaloks® mini found compatible with breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
In compliance with the recommended dosing regimen side effects are rare.
To indicate the incidence of undesirable side effects, use the following classification of the World Health Organization: – infrequent> 0.1% and
Disorders of immune system: unknown frequency: hypersensitivity reactions such as itching, urticaria, angioedema, and anaphylaxis.
Disorders of the gastrointestinal tract: Uncommon: diarrhea, constipation.
Metabolic and Nutritional: unknown frequency: gipermagniemiya, giperalyuminemiya, hypophosphatemia (prolonged treatment or high doses, or dosage units upon receipt of the low content of phosphate in the food) which could lead to increased bone resorption, hypercalciuria, osteomalacia.
special instructions
If during the treatment of the symptoms of the gastrointestinal tract are preserved for more than 10 days or deterioration is observed, it is necessary to clarify the diagnosis and to carry out the correction of medical measures. Caution must be a 2-hour interval between the application of the drug and other Maaloks® mini preparations and 4-hour interval between drug intake Maaloks® small and fluoroquinolones (see “Interaction with other drugs”). Despite the fact that the drug is available without a prescription, before use of the drug during pregnancy and lactation (breastfeeding), as well as in adolescents and patients with renal and mild to moderate severity failure are advised to consult with a physician. Avoid prolonged drug administration Maaloks® mini renal impairment. When administering the drug Maaloks® mini patients with renal insufficiency mild to moderate severity must be carefully controlled plasma concentrations of aluminum and magnesium, and in the case of increasing the use of the preparation should be discontinued immediately. Algeldrat low phosphate content in the diet may lead to deficiency of phosphorus in the body. Therefore, when it is applied, particularly long, should ensure adequate intake of dietary phosphate. In one mini-package formulation contains 3.15 g of sucrose and 0.2 g of sorbitol (corresponding to the maximum daily dose is contained 37.80 grams of sucrose and 2.4 g of sorbitol).
Effects on ability to drive vehicles and operate machinery
The drug does not affect the ability to drive vehicles and operate machinery.
Storage conditions
Store at a temperature not higher than 25 C.
Keep out of the reach of children!.
Dosing and Administration
Adults and children over 15 years.
Content 1-2 mini packets over 1-1.5 hours. After meals or at occurrence of heartburn. Before you open the mini-package should be mixed carefully its contents, carefully stretching the package between his fingers. Content squeeze the package in a spoon or in the mouth (to accept slurry without dilution). If necessary to take additional dose two hours after the previous administration. The maximum daily dose of 12 mini-packages. The course of treatment should not exceed 2-3 months. If episodic application (e.g., discomfort after errors in the diet) – take 1-2 mini packet once. In renal insufficiency mild maximum daily dose of eight mini-packets, renal insufficiency moderate maximum daily dose is 6 mini-packets.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist